1. |
|
|
2. |
- Larsson, Gunnel, et al.
(författare)
-
Importance-satisfaction discrepancies are associated with health-related quality of life in five-year survivors of endocrine gastrointestinal tumours
- 1999
-
Ingår i: Annals of Oncology. - 0923-7534 .- 1569-8041. ; 10:11, s. 1321-1327
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Little is known about the health-related-quality of life (HRQoL) of patients with endocrine gastrointestinal tumours. In this study, HRQoL was investigated in long-term survivors of endocrine GI tumours. Patients and methods: A questionnaire including the EORTC QLQ-C30 and ratings of importance of and satisfaction with a variety of HRQoL aspects was mailed to patients with carci-noid tumours (n = 64), or endocrine pancreatic tumours (EPT, n = 55). Median time since diagnosis was 120 months (range 60–360). The majority of patients (77 of 119) had ongoing treatment. Results: The EORTC QLQ-C30 ratings suggest that in spite of a long disease duration and treatment, patients perceived their HRQoL as relatively good. There were no major differences in HRQoL ratings between patients with carcinoid tumours and those with EPT. Patients whose ratings of importance was higher than their ratings of satisfaction with a specific HRQoL aspect also evidenced a low HRQoL for that aspect. Conclusions: The results indicate that survivors of endocrine GI tumours enjoy a relatively good HRQoL and suggest that importance < satisfaction discrepancies identify patients with a low quality of life.
|
|
3. |
- Tiensuu Janson, Eva, et al.
(författare)
-
Carcinoid tumors : analysis of prognostic factors and survival in 301 patients from a referral center
- 1997
-
Ingår i: Annals of Oncology. - 0923-7534 .- 1569-8041. ; 8:7, s. 685-690
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND:Little is known about factors related to prognosis in patients with carcinoid disease. In this study we have tried to identify such factors.PATIENTS AND METHODS:We have evaluated 301 consecutive carcinoid patients (256 midgut, 39 foregut and six hindgut) referred during 15 years for medical treatment with respect to tumor distribution, hormone production, prognostic factors and survival.RESULTS:Survival was significantly shorter in midgut carcinoid patients with > or = 5 liver metastases or with high levels of urinary 5-hydroxyindoleacetic acid, plasma chromogranin A or neuropeptide K. By univariate analysis, these variables together with the presence of carcinoid syndrome were related to a higher risk of dying. In multivariate analyses, performed in the 71 patients with full information on all variables, advanced age and plasma chromogranin A > 5000 micrograms/l were independent predictors of overall survival.CONCLUSIONS:Poor prognostic factors for midgut carcinoid patients were multiple liver metastases, presence of carcinoid syndrome and high levels of the tumor markers studied. In this study the only independent predictors of bad prognosis in midgut, carcinoid patients were advanced age, which however is inherently related to overall survival, and plasma chromogranin A > 5000 micrograms/l. Thus, chromogranin A may prove to be an important prognostic marker for patients with carcinoid tumors.
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
- Bjorkholm, M
(författare)
-
How much chemotherapy in advanced Hodgkin's disease?
- 1997
-
Ingår i: Annals of oncology : official journal of the European Society for Medical Oncology. - 0923-7534. ; 8:12, s. 1281-1283
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
8. |
|
|
9. |
|
|
10. |
|
|
11. |
|
|
12. |
|
|
13. |
|
|
14. |
|
|
15. |
|
|
16. |
- Jerkeman, Mats, et al.
(författare)
-
CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial
- 1999
-
Ingår i: Annals of Oncology. - 1569-8041. ; 10:9, s. 1079-1086
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: The long-term survival of patients with advanced stage aggressive lymphoma has not improved significantly during the last twenty years. In a randomised trial, the efficacy of MACOP-B, a six-drug weekly chemotherapy regimen, was compared to CHOP, the current standard regimen, in terms of overall and failure-free survival, toxicity and health related quality of life. PATIENTS AND METHODS: Four hundred five patients with aggressive lymphoma, stage II-IV, age 18-67, were randomised to receive either 12 weeks of MACOP-B or 8 courses of CHOP over 24 weeks. Special emphasis was put in the definition of Ann Arbor stage in extranodal disease. A subset of 95 patients also entered a quality of life study, based on the EORTC QLQ-C30. RESULTS: Thirty-one patients were ineligible. Among the remaining 374 patients, the median age was 52 years. According to the age-adjusted International Prognostic Index, 37% were 'high-intermediate' or 'high-risk' patients. No difference could be demonstrated, either in overall survival (60% at five years in the MACOP-B group and 59% in the CHOP group) or in failure-free survival (47% at five years with MACOP-B and 44% with CHOP). In terms of quality of life, physical function and global quality of life were more impaired in patients receiving MACOP-B, who also exhibited more non-haematological toxicity. CONCLUSION: No superiority of MACOP-B compared to CHOP could be demonstrated. CHOP remains the treatment of choice in low-risk patients. At present, intensified or experimental treatment should be reserved for high-risk disease.
|
|
17. |
|
|
18. |
|
|
19. |
|
|
20. |
|
|